最新发布
AI Model Predicts Cancer Treatment Response from Tumor Genotype
Researchers at University of California, San Diego have developed a new artificial intelligence (AI) model that can translate a tumor’s complex genetic profile into predictions about how that cancer may respond to treatment. The foundation model, called MutationProjector, was trained on genomic data from more than 30,000 tumors across 10 solid cancer types, and validated through testing across multiple independent patient cohorts. Led by Trey Ideker, PhD, professor of medicine at UC San Diego School of Medicine and director of the Big Data Institute at the University of Oxford, the researchers say the model offers a new framework for connecting cancer mutations to the biological pathways that drive treatment response.
Global Times: Chinese, Bangladeshi, Pakistani Researchers Gather In Shanghai To Breed Better Fish And Closer Ties
May 2026, Shanghai: At five o’clock on a misty morning in Xinchang Town of suburban Shanghai, the fog has yet to l…
Expocitros 开幕式将重点放在 HLB、生产力和市场上。
第51届Expocitros柑橘博览会、第47届柑橘周和第57届柑橘种植者日于今日(5月26日)在圣保罗州科尔代罗波利斯市的西尔维奥·莫雷拉柑橘中心/IAC正式开幕。本次活动重点关注应对黄龙病(HLB)的必要性、提高生产效率、改善成本管理以及评估果园中期经济可持续性。
FAO Director-General Calls for AI’s Transformative Power To Be At The Service Of Rural Communities And A Bridge Towards Shared Prosperity
May 2026, Rome: The Director-General of the Food and Agriculture Organization of the United Nations (FAO), QU Dongyu, to…
How to sell the next wave of gene-edited crops? Let the little guys do it
“We don’t want to repeat the debacle of GMOs,” Corteva Catalyst’s Mathias Müller said at the recent F&A Next Summit …
StrainX Bioworks Raises $13M to Scale Precision Fermentation Platform in India
Indian startup StrainX Bioworks has raised $13 million to expand its precision fermentation platform for nutritional and flavor ingredients as it moves toward commercial production.
AI颠覆作物保护研发范式丨拜耳CropKey创始人亲临CPEW 2026解析研发革命
人工智能正在重写农药研发的底层逻辑——不是优化现有流程,而是从根本上改变"如何发现下一个有效分子"这个问题本身。这套方法的创造者,将亲自来到CPEW 2026的现场。
Adcendo inks MSD supply deal to run ADC-Keytruda combination study
Copenhagen-based Adcendo plans to start a Phase Ib trial of the combination in the second half of the year. Participants will receive ADCE-T02, Adcendo’s tissue factor (TF)-directed ADC, with the anti-PD-1 checkpoint inhibitor Keytruda. Adcendo, which will sponsor the trial, began a Phase I monotherapy trial of ADCE-T02 in 2024.
四川省推进化工园区安全整治提升行动
大农化网报道:5月20日,从四川省应急管理厅传出消息,四川省持续深化化工园区安全整治提升行动,通过资金加持、专家帮扶、智能赋能、标准引领等多项举措,全省化工园区本质安全水平与综合治理能力显著提升,目前已有35个化工园区成功达到D级低风险等级…
Zoomlion opens Latin America hub
The new center integrates product display, technical training, after-sales support, maintenance services, and customer experience, aiming to build a comprehensive service platform covering the entire Latin American market. As a key strategic hub for the region, it will showcase agricultural equipment and a complete spare parts system while providing localized and professional lifecycle support services.
